Current Report Filing (8-k)
October 26 2017 - 4:09PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): October 25, 2017
MATINAS
BIOPHARMA HOLDINGS, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
001-38022
|
|
46-3011414
|
(State
or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
ID Number)
|
1545
Route 206 South, Suite 302
Bedminster,
New Jersey
|
|
07921
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (908) 443-1860
Not
Applicable
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [X]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
[X]
Item
5.07 Submission of Matters to a Vote of Security Holders
At
the Annual Meeting of Stockholders of the Company held on October 25, 2017, our stockholders voted on the two proposals listed
below. The proposals are described in detail in the Company’s definitive proxy statement for the Annual Meeting filed with
the Securities and Exchange Commission on September 14, 2017 (the “Proxy Statement”). The final results for the votes
regarding each proposal are set forth below.
1.
Our stockholders elected the following individuals to serve on our board of directors until the annual meeting of shareholders
to be held in 2018. The tabulation of votes with respect to the election of such directors was as follows:
|
|
|
|
|
AUTHORITY
|
|
|
BROKER
|
|
|
|
FOR
|
|
|
WITHELD
|
|
|
NON-VOTE
|
|
Herbert Conrad
|
|
|
24,309,157
|
|
|
|
571,398
|
|
|
|
27,694,436
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Roelof Rongen
|
|
|
24,838,874
|
|
|
|
41,681
|
|
|
|
27,694,436
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Eric Ende
|
|
|
24,839,694
|
|
|
|
40,861
|
|
|
|
27,694,436
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stefano Ferrari
|
|
|
24,839,544
|
|
|
|
41,011
|
|
|
|
27,694,436
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adam Stern
|
|
|
24,839,589
|
|
|
|
40,966
|
|
|
|
27,694,436
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
James Scibetta
|
|
|
24,839,589
|
|
|
|
40,966
|
|
|
|
27,694,436
|
|
2.
Our stockholders approved the ratification of the appointment of EisnerAmper LLP as the Company’s independent registered
public accounting firm for the fiscal year ending December 31, 2017. The tabulation of votes with respect to this proposal was
as follows:
For
|
|
|
Against
|
|
|
Abstain
|
|
|
Broker Non-Votes
|
|
|
51,796,081
|
|
|
|
778,510
|
|
|
|
400
|
|
|
|
—
|
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
MATINAS
BIOPHARMA HOLDINGS, INC.
|
|
|
Date: October 26,
2017
|
/s/
Roelof Rongen
|
|
Roelof
Rongen, Chief Executive Officer
|
Matinas Biopharma (AMEX:MTNB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Matinas Biopharma (AMEX:MTNB)
Historical Stock Chart
From Apr 2023 to Apr 2024